Literature DB >> 27406108

Stroke Treatment Academic Industry Roundtable Recommendations for Individual Data Pooling Analyses in Stroke.

Kennedy R Lees1, Pooja Khatri2.   

Abstract

Pooled analysis of individual patient data from stroke trials can deliver more precise estimates of treatment effect, enhance power to examine prespecified subgroups, and facilitate exploration of treatment-modifying influences. Analysis plans should be declared, and preferably published, before trial results are known. For pooling trials that used diverse analytic approaches, an ordinal analysis is favored, with justification for considering deaths and severe disability jointly. Because trial pooling is an incremental process, analyses should follow a sequential approach, with statistical adjustment for iterations. Updated analyses should be published when revised conclusions have a clinical implication. However, caution is recommended in declaring pooled findings that may prejudice ongoing trials, unless clinical implications are compelling. All contributing trial teams should contribute to leadership, data verification, and authorship of pooled analyses. Development work is needed to enable reliable inferences to be drawn about individual drug or device effects that contribute to a pooled analysis, versus a class effect, if the treatment strategy combines ≥2 such drugs or devices. Despite the practical challenges, pooled analyses are powerful and essential tools in interpreting clinical trial findings and advancing clinical care.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  clinical trial; meta-analysis as topic; randomized controlled trial; stroke

Mesh:

Year:  2016        PMID: 27406108      PMCID: PMC4961517          DOI: 10.1161/STROKEAHA.116.012966

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  15 in total

1.  Standardizing the structure of stroke clinical and epidemiologic research data: the National Institute of Neurological Disorders and Stroke (NINDS) Stroke Common Data Element (CDE) project.

Authors:  Jeffrey L Saver; Steven Warach; Scott Janis; Joanne Odenkirchen; Kyra Becker; Oscar Benavente; Joseph Broderick; Alexander W Dromerick; Pamela Duncan; Mitchell S V Elkind; Karen Johnston; Chelsea S Kidwell; James F Meschia; Lee Schwamm
Journal:  Stroke       Date:  2012-02-02       Impact factor: 7.914

2.  Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement.

Authors:  Lesley A Stewart; Mike Clarke; Maroeska Rovers; Richard D Riley; Mark Simmonds; Gavin Stewart; Jayne F Tierney
Journal:  JAMA       Date:  2015-04-28       Impact factor: 56.272

3.  A collaborative sequential meta-analysis of individual patient data from randomized trials of endovascular therapy and tPA vs. tPA alone for acute ischemic stroke: ThRombEctomy And tPA (TREAT) analysis: statistical analysis plan for a sequential meta-analysis performed within the VISTA-Endovascular collaboration.

Authors:  Rachael L MacIsaac; Pooja Khatri; Martin Bendszus; Serge Bracard; Joseph Broderick; Bruce Campbell; Alfonso Ciccone; Antoni Dávalos; Stephen M Davis; Andrew Demchuk; Hans-Christoph Diener; Diederik Dippel; Geoffrey A Donnan; Jens Fiehler; David Fiorella; Mayank Goyal; Werner Hacke; Michael D Hill; Reza Jahan; Edward Jauch; Tudor Jovin; Chelsea S Kidwell; David Liebeskind; Charles B Majoie; Sheila Cristina Ouriques Martins; Peter Mitchell; J Mocco; Keith W Muir; Raul Nogueira; Jeffrey L Saver; Wouter J Schonewille; Adnan H Siddiqui; Götz Thomalla; Thomas A Tomsick; Aquilla S Turk; Philip White; Osama Zaidat; Kennedy R Lees
Journal:  Int J Stroke       Date:  2015-09-09       Impact factor: 5.266

4.  Adopting a Patient-Centered Approach to Primary Outcome Analysis of Acute Stroke Trials Using a Utility-Weighted Modified Rankin Scale.

Authors:  Napasri Chaisinanunkul; Opeolu Adeoye; Roger J Lewis; James C Grotta; Joseph Broderick; Tudor G Jovin; Raul G Nogueira; Jordan J Elm; Todd Graves; Scott Berry; Kennedy R Lees; Andrew D Barreto; Jeffrey L Saver
Journal:  Stroke       Date:  2015-07-02       Impact factor: 7.914

5.  Quantifying the value of stroke disability outcomes: WHO global burden of disease project disability weights for each level of the modified Rankin Scale.

Authors:  Keun-Sik Hong; Jeffrey L Saver
Journal:  Stroke       Date:  2009-10-01       Impact factor: 7.914

6.  An improved method for simple, assumption-free ordinal analysis of the modified Rankin Scale using generalized odds ratios.

Authors:  Leonid Churilov; Sarah Arnup; Hayden Johns; Tiffany Leung; Stuart Roberts; Bruce C V Campbell; Stephen M Davis; Geoffrey A Donnan
Journal:  Int J Stroke       Date:  2014-09-04       Impact factor: 5.266

7.  A simple, assumption-free, and clinically interpretable approach for analysis of modified Rankin outcomes.

Authors:  George Howard; Jennifer L Waller; Jenifer H Voeks; Virginia J Howard; Edward C Jauch; Kennedy R Lees; Fenwick T Nichols; Volker W Rahlfs; David C Hess
Journal:  Stroke       Date:  2012-02-16       Impact factor: 7.914

8.  The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.

Authors:  Peter Sandercock; Joanna M Wardlaw; Richard I Lindley; Martin Dennis; Geoff Cohen; Gordon Murray; Karen Innes; Graham Venables; Anna Czlonkowska; Adam Kobayashi; Stefano Ricci; Veronica Murray; Eivind Berge; Karsten Bruins Slot; Graeme J Hankey; Manuel Correia; Andre Peeters; Karl Matz; Phillippe Lyrer; Gord Gubitz; Stephen J Phillips; Antonio Arauz
Journal:  Lancet       Date:  2012-05-23       Impact factor: 79.321

Review 9.  Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis.

Authors:  Joanna M Wardlaw; Veronica Murray; Eivind Berge; Gregory del Zoppo; Peter Sandercock; Richard L Lindley; Geoff Cohen
Journal:  Lancet       Date:  2012-05-23       Impact factor: 79.321

10.  Details of a prospective protocol for a collaborative meta-analysis of individual participant data from all randomized trials of intravenous rt-PA vs. control: statistical analysis plan for the Stroke Thrombolysis Trialists' Collaborative meta-analysis.

Authors: 
Journal:  Int J Stroke       Date:  2013-05-03       Impact factor: 5.266

View more
  5 in total

1.  Do you dare with a health-economy methodology issue? An editorial comment on "A systematic review of cost-effectiveness analyses on endovascular thrombectomy in ischemic stroke patients".

Authors:  Albert Pons-Escoda
Journal:  Eur Radiol       Date:  2022-03-31       Impact factor: 5.315

2.  Improving Visualization Methods of Utility-Weighted Disability Outcomes for Stroke Trials.

Authors:  Ivie Tokunboh; Eleanor Mina Sung; Fiona Chatfield; Nathan Gaines; May Nour; Sidney Starkman; Jeffrey L Saver
Journal:  Front Neurol       Date:  2022-05-13       Impact factor: 4.086

3.  Classification of Different Degrees of Disability Following Intracerebral Hemorrhage: A Decision Tree Analysis from VISTA-ICH Collaboration.

Authors:  Thanh G Phan; Jian Chen; Richard Beare; Henry Ma; Benjamin Clissold; John Van Ly; Velandai Srikanth
Journal:  Front Neurol       Date:  2017-02-28       Impact factor: 4.003

4.  Utility-Weighted Modified Rankin Scale as Primary Outcome in Stroke Trials: A Simulation Study.

Authors:  Simone A Dijkland; Daphne C Voormolen; Esmee Venema; Bob Roozenbeek; Suzanne Polinder; Juanita A Haagsma; Daan Nieboer; Vicky Chalos; Albert J Yoo; Jennifer Schreuders; Aad van der Lugt; Charles B L M Majoie; Yvo B W E M Roos; Wim H van Zwam; Robert J van Oostenbrugge; Ewout W Steyerberg; Diederik W J Dippel; Hester F Lingsma
Journal:  Stroke       Date:  2018-03-13       Impact factor: 7.914

5.  Predicting 90-day modified Rankin Scale score with discharge information in acute ischaemic stroke patients following treatment.

Authors:  Andrew K ElHabr; Jeffrey M Katz; Jason Wang; Mehrad Bastani; Gabriela Martinez; Michele Gribko; Danny R Hughes; Pina Sanelli
Journal:  BMJ Neurol Open       Date:  2021-06-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.